The global telehealth market reached $191.88 billion in 2026, up from $153.84 billion the year before, and industry forecasts converge on it reaching somewhere near $1.4 trillion by 2035 — a sustained growth rate above 24% annually. That's not evenly distributed across every category. Some segments are expanding fast enough to reshape what "telehealth" even means; others are settling into steady, unglamorous maturity.
Where the growth is concentrated
Mental health remains the largest single use case by far — nearly 70% of all telehealth claim lines, more than 36 times the next largest category. But the fastest percentage growth right now is happening in narrower segments: AI-driven clinical infrastructure (documentation, triage, provider matching), metabolic health and GLP-1 programs, and longevity-adjacent care like TRT, HRT, and peptide therapies.
What "fast growth" actually signals about a platform
Rapid category growth cuts both ways for the person choosing a provider.
The upside
- More competition, which tends to push pricing down and features up, as new entrants compete for the same growing pool of patients
- Faster innovation in genuinely useful areas — better intake experiences, more treatment format options, improved follow-up tools
- More specialized options, since a growing market supports niche platforms that wouldn't have been viable a few years ago
The risk
New entrants scaling faster than their clinical infrastructure. A platform that's grown 10x in a year has had to hire, train, and onboard providers at a pace that's genuinely hard to do well — which is part of what the Yale secret shopper study's findings likely reflect at an industry level.
Venture-funded growth prioritizing acquisition over retention. A platform burning capital to acquire patients fast isn't necessarily the same platform investing in the follow-up care that keeps them healthy long-term.
The categories worth watching specifically
- Metabolic health / GLP-1 — still the highest-dollar growth category in consumer telehealth, with total GLP-1-related sales projected to exceed $100 billion by 2030 across all channels
- Longevity and hormone therapy — TRT, HRT, and peptide programs (Sermorelin, NAD+) are increasingly bundled into broader "whole health" telehealth offerings rather than sold as standalone services
- AI-assisted clinical infrastructure — not a patient-facing category exactly, but the layer increasingly determining how every other category actually operates behind the scenes
- Asia-Pacific market expansion — the fastest-growing region globally, which will likely shape which international telehealth companies eventually enter the U.S. market
What this means for choosing a provider today
Fast growth alone isn't a reason to trust or distrust a platform. What matters is whether growth has been matched by investment in the parts patients don't see on the homepage — provider credentialing, follow-up infrastructure, pharmacy partnerships. Ask how long a platform has operated in your specific state, not just how big it's gotten overall.
A market growing 24% a year rewards genuine innovation and rewards cutting corners at almost the same rate. Both look identical from the landing page.
An established platform in a fast-growing category
The provider below has scaled within the metabolic health category while maintaining documented clinical processes.
A platform scaling within its clinical infrastructure
Ageless is one of the newer entrants in the metabolic and longevity space, worth evaluating on the same fundamentals as any established provider — licensing, follow-up structure, and transparent pricing.
See Ageless's program → Paid linkThe bottom line
A growing market is a healthy sign for the category overall — more competition, more innovation, more options. It's not, on its own, a signal about any individual platform's quality. The fastest-growing provider in a hot category and the most careless one can look identical from the outside. The fundamentals from earlier in this series — verified licensing, real follow-up structure, transparent pricing — still do the actual work of telling them apart.